Regis Healthcare: Opportunity hiding in plain sight

Sometimes the most compelling investments are the ones everyone else is looking past. Regis Healthcare (ASX: REG) is one such opportunity.

REG has slumped >50% from its 52-week highs. Reported net tangible assets are negative. The dividend payout ratio exceeds 100%. On every traditional screen, this looks like a business in trouble. However, look more closely and the picture inverts completely.

In May 2026, Stonepeak paid $2.5 billion to acquire Estia Health, Australia's second largest aged care operator. The transaction valued Estia at $270,000 per bed and 14.2 times EBITDA. Bain Capital, who had owned Estia since 2023, tripled their money in under three years after taking the business private off the ASX. The private equity community has decisively voted on what quality aged care operators are worth.

Yet Regis: equal in revenue, 100% freehold owned, debt free with $170 million in net cash, and genuinely profitable with $55.7 million NPAT, trades at just $144,000 per bed.

A 47% discount to the price Stonepeak just paid for a lower quality portfolio.

The disconnect exists because most investors fundamentally misunderstand the balance sheet of aged care providers. Regis carries $2.28 billion of Refundable Accommodation Deposits as a liability. But these are interest-free, government-guaranteed, and perpetual at the portfolio level. They function economically as zero-cost permanent capital. Treating them as traditional debt distorts every valuation metric.

If you reframe RADs as what they actually are and Regis trades at a mere 0.88 times adjusted book value, well below the average since listing at 1.10x adjusted book value.

The structural tailwinds are undeniable as Australia will need to deliver 10,600 new aged care beds annually for the next twenty years to satisfy demand. The sector is currently delivering just 800. Only well-capitalised operators with proven M&A platforms and development pipelines can respond. Regis has ten greenfield sites underway and $362 million of undrawn debt capacity.

There are 3 scenarios that could eventuate:

1. Regis executes operationally and re-rates toward its adjusted book value, delivering strong returns over the next 12 months.
2. A private equity bidder makes an approach, entirely plausible given the sector consolidation wave, and shareholders receive a significant premium to the current market price.
3. Neither occurs and investors collect a 4% fully-franked dividend while compounding earnings grow the business.

The downside is underpinned by real freehold assets in premium metropolitan catchments. The upside includes multiple independent catalysts. Insiders were buying meaningful amounts of stock at levels 35% above current prices.

Markets occasionally offer asymmetric opportunities to those willing to look past the headline accounting. Regis Healthcare at current prices is one of them.